Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, 2333 Leiden, The Netherlands.
Cold Spring Harb Perspect Med. 2012 Apr;2(4):a007781. doi: 10.1101/cshperspect.a007781.
Type 1 diabetes is characterized by recognition of one or more β-cell proteins by the immune system. The list of target antigens in this disease is ever increasing and it is conceivable that additional islet autoantigens, possibly including pivotal β-cell targets, remain to be discovered. Many knowledge gaps remain with respect to the disorder's pathogenesis, including the cause of loss of tolerance to islet autoantigens and an explanation as to why targeting of proteins with a distribution of expression beyond β cells may result in selective β-cell destruction and type 1 diabetes. Yet, our knowledge of β-cell autoantigens has already led to translation into tissue-specific immune intervention strategies that are currently being assessed in clinical trials for their efficacy to halt or delay disease progression to type 1 diabetes, as well as to reverse type 1 diabetes. Here we will discuss recently gained insights into the identity, biology, structure, and presentation of islet antigens in relation to disease heterogeneity and β-cell destruction.
1 型糖尿病的特征是免疫系统识别一种或多种β细胞蛋白。该疾病的靶抗原列表不断增加,可以想象,可能还存在其他胰岛自身抗原,包括关键的β细胞靶标有待发现。关于该疾病的发病机制,仍然存在许多知识空白,包括对胰岛自身抗原丧失耐受性的原因,以及为什么针对表达分布超出β细胞的蛋白质会导致选择性β细胞破坏和 1 型糖尿病。然而,我们对β细胞自身抗原的认识已经导致了针对组织特异性免疫干预策略的转化,这些策略目前正在临床试验中评估其有效性,以阻止或延迟向 1 型糖尿病的疾病进展,以及逆转 1 型糖尿病。在这里,我们将讨论最近在与疾病异质性和β细胞破坏有关的胰岛抗原的身份、生物学、结构和呈递方面获得的新见解。